BHCM
ITOS

Brevan Howard Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Brevan Howard Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,705
Closed -$249K – 1158
2023
Q4 		$249K Buy
+22,705
New +$225K ﹤0.01% 800

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Brevan Howard Capital Management's ITOS Position: Q1 2024 in Review

Brevan Howard Capital Management sold out of iTeos Therapeutics (ITOS) in Q1 2024, closing a stake of 22,705 shares — an estimated $249K sold.

Brevan Howard Capital Management first reported a position in ITOS in Q4 2023 and held it in 1 quarter. The position peaked at $249K in Q4 2023. 135 funds tracked by Wall St. Rank hold ITOS as of Q1 2024.

  • Brevan Howard Capital Management reported no remaining iTeos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 22,705 iTeos Therapeutics shares in Q1 2024, an estimated $249K.
  • Brevan Howard Capital Management first reported a position in iTeos Therapeutics in Q4 2023 and held it in 1 quarter.
  • Brevan Howard Capital Management's iTeos Therapeutics position peaked at $249K in Q4 2023.
  • 135 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2024.

Based on Brevan Howard Capital Management's 13F filing for Q1 2024, filed 15 May 2024.